Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05303467 · ClinicalTrials.gov registry record · Phase 1
A Feasibility Study to Evaluate the Safety of the TheraSphere Glioblastoma (GBM) Device in Patients With Recurrent GBM
A Phase 1 study of Glioblastoma Multiforme and Recurrent Glioblastoma, sponsored by Boston Scientific Corporation.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
- 9
- Study locations
NCT05303467: Recruiting Phase 1 study of Glioblastoma Multiforme and Recurrent Glioblastoma, sponsored by Boston Scientific Corporation.
NCT05303467 is a Phase 1 study of Glioblastoma Multiforme and Recurrent Glioblastoma that is actively recruiting participants, run by Boston Scientific Corporation. The registered enrollment target is 36 participants, below the 96-participant average among 88 other Glioblastoma Multiforme trials with a reported enrollment target (62% lower). The trial reports 9 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05303467, a Phase 1 study of Glioblastoma Multiforme and Recurrent Glioblastoma, is actively recruiting participants, sponsored by Boston Scientific Corporation.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
- 9
- Study locations
Study Summary
The FRONTIER Study is a prospective, interventional, single-arm, multi-center, study to assess the safety and technical feasibility of TheraSphere GBM in patients with recurrent GBM.
Conditions Studied
Interventions
- DEVICE TheraSphere GBM
Study Locations (9)
California
- University of California San Diego - San Diego
- University of California San Francisco - San Francisco
Alabama
- University of Alabama Birmingham - Birmingham
Florida
- Mayo Jacksonville - Jacksonville
Illinois
- Northwestern Univerity - Chicago
Maryland
- Johns Hopkins Interventional Radiology Center - Baltimore
Missouri
- Washington University School of Medicine - St Louis
New York
- Lenox Hill Hospital - New York
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2022-07-30 |
| Est. Completion | 2027-01-31 |
| Phase | Phase 1 |
What NCT05303467 shows while recruiting
NCT05303467 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 96-participant average among 88 other Glioblastoma Multiforme trials with a reported enrollment target (62% lower).
The record links to 2 conditions, with Glioblastoma Multiforme appearing as the primary indexed condition, and to 1 intervention - of which TheraSphere GBM is the first listed.
NCT05303467 lists 9 locations in 8 states (California, Alabama, Florida).
Frequently Asked Questions
What is clinical trial NCT05303467 about?
NCT05303467 is a clinical study titled "A Feasibility Study to Evaluate the Safety of the TheraSphere Glioblastoma (GBM) Device in Patients With Recurrent GBM". The FRONTIER Study is a prospective, interventional, single-arm, multi-center, study to assess the safety and technical feasibility of TheraSphere GBM in patients with recurrent GBM.
What is the current status of trial NCT05303467?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2022-07-30. Estimated completion is 2027-01-31.
What conditions does trial NCT05303467 study?
This clinical trial studies the following conditions: Glioblastoma Multiforme, Recurrent Glioblastoma.
What interventions are being tested in trial NCT05303467?
The interventions under investigation include: TheraSphere GBM (DEVICE).
Who is sponsoring clinical trial NCT05303467?
This trial is sponsored by Boston Scientific Corporation, which has 280 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05303467 being conducted?
This trial has 9 study locations across Alabama, California, Florida, Illinois, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioblastoma Multiforme
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05303467's enrollment target sits among peer trials
36 52nd of 88 higher than 34 of 88 other Glioblastoma Multiforme trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Glioblastoma Multiforme trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Trial of Anti-PD-1 Immunotherapy and Stereotactic Radiation in Patients With Recurrent Glioblastoma
RECRUITING · Phase 1
-
Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects
RECRUITING · Phase 1
-
Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age
RECRUITING · Phase 1
-
Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma.
RECRUITING · Phase 1
-
HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
RECRUITING · Phase 1
-
Autologous CAR-T Cells Targeting B7-H3 in Recurrent or Refractory GBM CAR.B7-H3Tc
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00929006 · 36 participants · Early Phase 1
Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism
- NCT01891318 · 36 participants · Phase 1
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
- NCT02291848 · 36 participants · Phase 1
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
- NCT02366819 · 36 participants · Phase 4
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI